Biotechnology company AAVantgarde Bio has raised $141 million to advance its clinical programmes in inherited retinal disorders (IRD) Stargardt disease and Usher 1B syndrome.  The investment follows a successful Series B financing round, led by Schroders Capital and existing investors Atlas Venture and Forbion.   AAVantgarde aims to use the proceeds to complete the clinical study of AAVB-039 as a treatment for Stargardt […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!